Weight-loss drugs can cut costs long-term. But who's paying now?

Eli Lilly said in August that around 50 percent of employers had chosen to cover its weight-loss drug, Zepbound, little changed from a year earlier. Novo Nordisk said last month that about 40 million people have access to anti-obesity drug Wegovy through commercial insurance, roughly the same as at the end of 2023.. Eli Lilly and Novo Nordisk, which dominate the…